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Abstract
There is a debate whether post-streptococcal reactive arthritis (PSRA) is a separate entity or a condition on the
spectrum of acute rheumatic fever (ARF). We believe that PSRA is a distinct entity and in this paper we review the
substantial differences between PSRA and ARF. We show how the demographic, clinical, genetic and treatment
characteristics of PSRA differ from ARF. We review diagnostic criteria and regression formulas that attempt to
classify patients with PSRA as opposed to ARF. The important implication of these findings may relate to the issue
of prophylactic antibiotics after PSRA. However, future trials will be necessary to conclusively answer that question.
Introductory case 1
An 8 year old boy, previously healthy, presented to the
rheumatology clinic with a three week history of right
hip pain and one week history of pain in the right knee,
without fever. He was diagnosed with streptoccocal ton-
silitis one month ago. For his joint complaints he was
treated with acetylsalicylic acid for three weeks, with
minimal improvement. There was no past personal or
family history of arthritis.
On examination, arthritis was found in both the right
hip and the right knee. There was no evidence of
erythema marginatum, chorea, subcutaneous nodules or
cardiac murmurs. The complete blood count was nor-
mal, the erythrocyte sedimentation rate (ESR) was 40
mm/hr and antistreptolysin O (ASLO) level was 700 IU/
mL. The echocardiogram was normal.
What is the diagnosis? What is the recommended
therapy?
Introductory case 2
A 12 years old girl, previously healthy, presented to the
emergency room with 2 days of left knee pain and fever,
and was admitted to the pediatric ward for further
assessment. She was diagnosed with streptoccocal tonsi-
litis one month ago. On examination, she had arthritis
of the left knee, with no other significant findings. Her
complete blood count was normal, the ESR was 90 mm/
hr and the ASLO level was 800 IU/mL.
A knee aspirate was completed: synovial fluid had
50,000 white blood cells/mm3 with a predominance of
neutrophils. After a day in the hospital, the left knee
arthritis disappeared and arthritis of the left hip was
detected. She also continued to have fever.
What is the diagnosis? What is the recommended
therapy?
Introductory case 3
A 6 year old girl, previously healthy, presented to the
pediatric clinic with a four day history of left knee pain.
She had no fever at presentataion, and no history of
tonsilitis in the last month. There was no history of
trauma. On examination, she had arthritis of the left
knee, with no other significant findings. Her complete
blood count was normal, the ESR was 60 mm/hr and
the ASLO level was 600 IU/mL.
A knee aspirtate was performed: The synovial fluid
had 10,000 white blood cells/mm3 with a predominance
of monocytes. On follow up there was no involvement
of other joints.




Post infectious arthritis is defined as arthritis which
develops during or soon after an infection elsewhere in
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the body, but in which the microorganisms cannot be
recovered from the joint [1].
The classical pathogens described in association with
post infectous arthritis in young children are enteric
pathogens: Salmonella, Shigella, Campylobacter and Yer-
sinia. Chlamydia trachomatis is a genital pathogen,
which is also known to cause this condition [2]. When
these pathogens are involved, the arthritis is termed
“Reactive Arthritis” (ReA). Patients with ReA are fre-
quently positive for HLA-B27, and the clinical picture
resembles other spondyloarthropathies.
Other infection and post infectious arthritides are
caused by viral infections (especially rubella, mumps,
hepatitis B and parvovirus), Mycoplasma genitalium,
Ureaplasma urealyticum, Chlamydia pneumonia, Neis-
seria gonorrhea, and vaccinations with some of the live
vaccines. Post infectious arthritis related to b-hemolytic
group A streptococcus (GAS) is the focus of this paper.
Streptococcal post-infectious arthritis
The classic condition related to arthritis following throat
infections with GAS is acute rheumatic fever (ARF). The
diagnosis of ARF is established largely on clinical
grounds. The initial description of the clinical manifesta-
tions, now known as the “Jones criteria”, was published
by Jones in 1944 and revised most lately in 1992. The
major criteria (Table 1) include carditis, polyarthritis,
chorea, erythema marginatum and subcutaneous
nodules. The minor criteria include arthralgia (counted
only when arthritis is not present), fever, elevated acute
phase reactants and an electrocardiogram showing a
prolonged PR interval. If supported by evidence of a
preceding GAS infection, the presence of two major
manifestations or of one major and two minor manifes-
tations is indicative of a high probability of ARF [3].
Since 1959, there are reports of patients who present
with GAS post infectious arthritis and do not fulfill the
classical Jones criteria [4]. This condition is designated
as post-streptococcal reactive arthritis (PSRA). The
question whether PSRA is a distinct entity from ARF
has not yet been fully answered. There are some reports
of carditis developing after PSRA, suggesting that PSRA
may be part of the spectrum of ARF [5,6]. However,
since there are substantial clinical, immunological and
genetic differences between PSRA and ARF, we believe
PSRA to be a distinct entity [7-9]. This paper will review
the entity of PSRA and the major factors distinguishing
it from ARF.
Demographic characteristics of PSRA
The age distribution of PSRA appears to be bimodal;
with a peak at ages 8-14 years and another at age 21-37.
In contrast, ARF has a single peak incidence in child-
hood around 12 years, and ReA which has a single peak
incidence at 27-34 years [10]. Both genders are equally
affected, in all age groups.
Clinical characteristics of PSRA
Disease onset in relation to throat infection
Patients with both PSRA and ARF have arthritis that
follow a symptom free interval after an episode of GAS
pharyngitis/tonsilitis. In ARF, arthritis usually occurs 10-
28 days after the GAS pharyngitis while in PSRA arthri-
tis appears after a shorter “incubation” period, approxi-
mately 7-10 days after the infection. Simonini et al.
described 52 pediatric PSRA patients, in whom arthritis
appeared 4-12 days following pharyngitis [11].
Joint involvement (Table 2)
PSRA arthritis is additive and persistent, and can involve
large joints, small joints, or the axial skeleton. In ARF
the arthritis is migratory and transient, and usually
involves the large joints (small and axial joint involve-
ment may occur but is uncommon). In a study by Bar-
ash et al. 159 pediatric PSRA patients were compared to
Table 1 Jones criteria for the diagnosis of acute rheumatic fever (ARF)
The five major manifestations are
1 Polyarthritis (predominantly involving the large joints)
2 Carditis, valvulitis and pericarditis (eg, pancarditis)
3 Central nervous system involvement (eg, Sydenham chorea)
4 Erythema marginatum
5 Subcutaneous nodules
The four minor manifestations are
1 Arthralgia
2 Fever
3 Elevated acute phase reactants [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]
4 Prolonged PR interval
Supporting evidence of antecedent group A streptococcal infection,»
Postive throat culture or rapid streptococcal antigen test
Elevated or rising streptococcal antibody liter
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68 ARF patients [12]. Seventy-nine percent of the ARF
patients had migratory arthritis compared to 33% of the
PSRA patients, and 40% had symmetrical arthritis in the
ARF group compared to 22% in the PSRA group. In
another series, van Bemmel et al. described 60 adult
patients with PSRA [13]. Small joints were involved in
23% of the patients; large joints were involved in 58%,
and both types of joints in 18%. Symmetric distribution
was found in 60%. Involvement of upper limb joints was
found in 18%, lower limb in 50% and both in 32%. Risse
et al. described 21 pediatric patients with PSRA of
whom 57% had hip arthritis and 43% had knee and/or
ankle arthritis; 95% had monoarthritis and 5% oligoar-
thritis [14]. In all patients the arthritis was not migra-
tory. In the cohort of Simonini et al. monoarthritis
involving one large joint was found in 19 children and
arthritis involving 2 or 3 joints in 29 [11]. Thirty-seven
children had non-migratory arthritis.
Mackie et al. [10] conducted a systematic search on
Medline using strict inclusion criteria. They identified
188 cases of PSRA published in the literature between
1982-2002, both adult and pediatric. Eighty-two percent
had non-migratory arthritis, 23% monoarthritis, 37% oli-
goarthritis, and 37% polyarthritis. Forty-one percent had
symmetrical arthritis. The most frequently involved
joints were knee, ankle, wrist, and hip. Nine patients
had tenosynovitis.
Laboratory markers of inflammation
Barash et al. [12] demonstrated that the ESR and C-
reactive protein (CRP) levels were significantly higher in
ARF (92.2 mm/h and 10.7 mg/dL, respectively) com-
pared to PSRA patients (57 and 2.3, respectively).
Response to treatment and recurrence
The arthritis of ARF responds dramatically to acetylsa-
licylic acid or NSAIDs like naproxen. In contrast, the
response in PSRA is much more modest [7]. Barash et
al. reported that the resolution of arthritis after treat-
ment occurred in ARF patients after a mean of 2.2 days
compared to 6.9 days in the PSRA group [12]. Relapse
occurred in 7% of the ARF group compared with 21% of
the PSRA group. van Bemmel et al. described that joint
symptoms lasted a mean of 9.7 weeks in his adult PSRA
cohort [13]. In the cohort of Risse et al. 33% of PSRA
patients continued to have active arthritis after 6 weeks
of follow-up [14], while Simonini et al. the reported the
mean duration to resolution of symptoms was 54 days
[11]. Some patients may benefit from corticosteroid
treatment in the acute phase.
Diagnosis of PSRA
Ayoub et at proposed the following diagnostic criteria
[15]:
1. Arthritis of acute onset, symmetric or asymmetric,
usually non-migratory, which can affect any joint and is
persistent or recurrent. At best, the arthritis is poorly
responsive to salicylates or NSAIDs.
2. Evidence of antecedent GAS infection.
3. Failure to fulfill the modified Jones criteria for the
diagnosis of ARF.
Recently, Barash et al. suggested a regression mathe-
matical formula based on four significant diagnostic dis-
criminators to differentiate ARF from PSRA [12]:
-1.568 + 0.015 × ESR + 0.02 × CRP - 0.162 × days to
resolution of joint symptoms - 2.04 × return of joint
symptoms (yes = 1, No = 0)
If the result is greater than 0, the patient is classified
as having ARF; otherwise the patient is classified as hav-
ing PSRA. The sensitivity of this formula was 79% and
specificity 87.5% for a correct classification of PSRA.
Diagnosis of antecedent Streptococcal infection
In order to diagnose PSRA, evidence of prior GAS infec-
tion is necessary. Microbiological confirmation can be
obtained by throat culture or rapid antigen detection
tests (RADT). However, both throat culture and RADT
cannot differentiate a true GAS infection from a carrier
state, which can be found in as many as 15% of school
age children [7].
Serologic tests are another way of confirmation a
recent GAS infection. Elevated or increasing anti-strep-
tococcal antibody titters are of value in identifying a
preceding GAS infection in a patient suspected of hav-
ing PSRA. The most commonly used and commercially
available antibody assays are anti-streptolysin O (ASLO)
and anti-deoxyribonuclease B (anti-DNase-B).
ASLO titers begin to rise approximately 1 week, and
peak 3 to 6 weeks after the initial GAS infection. Anti-













Barash et al. [12] 159 pediatric 22 33 - - -
van Bemmel et al.
[13]
60 adults 60 - - - -
Risse et al. [14] 21 pediatric - 0 95 5 0
Simonini et al. [11] 52 pediatric - 29 36 56 8
Mackie et al. [10] 188 adults &
pediatrics
41 18 23 37 37
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DNase-B titers begin to rise 1-2 weeks and peak 6-8
weeks after the infection. Elevated titers for both tests
may persist for several months or even years after GAS
infection.
A problem in using anti-streptococcal antibody titters
in identifying a preceding GAS infection in the pediatric
population is that the normal levels of these antibodies
are higher among school aged children then among
adults [16]. The cutoff level of anti-streptococcal anti-
body titters that can be considered diagnostic for GAS
infection in children is still not clear. Cutoff values of
ASLO have ranged from 300-800 IU/ml and 200-800
IU/ml for anti-DNase-B. Some studies have required
that titers show a significant longitudinal change. For
example, Jansen et al. required a 26% increase in ASLO
titers, and 14% in anti-DNase-B titers for inclusion in
the study cohort [8,10,14].
It was suggested that levels greater than 2 standard
deviations of local laboratory norms, or a two fold
increase in the ASLO titer repeated 2-3 weeks after the
initial test confirm recent strep infection [8,10,14].
Although GAS is the major pathogen described as
causing PSRA other non-group A streptococci (NGAS),
including groups C and G, have also been associated
with PSRA [10,17]. Jansen et al. proposed differentiating
between GAS and NGAS infection in PSRA patients by
using an ASLO/anti-DNase-B ratio obtained 4-10 weeks
after a throat infection. A ratio less than 1.4 indicates
GAS as the cause while a ratio greater than 1.5 suggests
NGAS-induced PSRA [18].
Genetic markers in PSRA
There are several conflicting studies addressing the asso-
ciation of ARF and PSRA with class II HLA-DR anti-
gens. Ahmed et al. found an increased frequency of
HLA DRB1*01 in patients with PSRA compared with
healthy controls and patients with ARF [9]. In patients
with ARF, there was an increased frequency of the HLA
DRB1*16 allele when compared with control subjects.
This association may suggest that the etiology of PSRA,
as of ARF, may be related to the inheritance of certain
class II HLA alleles. In contrast Simonini et al. did not
find significance differences in frequency of various
HLA DRB1 alleles (including DRB1*01 and 16) between
25 patients with ARF, 34 with PSRA and healthy con-
trols [19].
In a study of Israeli patients, Harel et al. [20] has
found a significantly higher percentage of B cells expres-
sing the D8/17 antigen in patients with a history of ARF
than in control subjects. Later the same group investi-
gated the presence of D8/17 alloantigen on B cells from
patients with PSRA compared with control subjects [21].
There was a small but significant difference between the
expression of the antigen in patients with PSRA and
control subjects, but with significant overlap in the 2
groups. Moreover, there was a weak negative correlation
between the percentage of D8/17 positive cells and the
time elapsed from diagnosis. Therefore it is not clear
whether this alloantigen expression is truly a genetic
marker or is induced and regulated by the infection.
Carditis in PSRA
There are conflicting reports regarding the heart invol-
vement in PSRA. De Cunto et al. described 12 pediatric
patients who were diagnosed with PSRA [6]. One of the
patients in the group developed classic ARF with valvu-
litis 18 months after the initial episode. Similarly,
Ahmed et al. described 25 pediatric PSRA patients, one
of whom developed carditis 9 month from the onset of
arthritis [9]. In a retrospective study Moorthy et al.
described 40 pediatric patients with PSRA [22]. At base-
line, 18% (n = 7) had a finding noted on the echocardio-
gram such as mild mitral and/or aortic insufficiency, or
mitral valve prolapse, 2 patients with a normal baseline
echocardiogram may have developed findings after 12
months of follow-up (left ventricular systolic dysfunc-
tion, mitral, tricuspid and pulmonary insufficiency).
There other case reports and a small series of carditis in
PSRA patients [5].
In contrast, JM van Bemmel recently described 60
adult patients diagnosed with PSRA who were not trea-
ted with antibiotic prophylaxis [13]. After a median fol-
low up of 8.9 years there was no increased risk of
valvular heart disease compared to the control group.
Similarly, Simonini described 52 children with PSRA;
all were treated with antibiotic prophylaxis for one year
[11]. After a median followup of 8 years none of the
patients developed clinical or echocardiographic evi-
dence of valvular disease or cardiac involvement.
Barash et al. [12] described 152 pediatric PSRA
patients, none of whom developed carditis on followup
[12]. Despite the Jones criteria, discussing only physical
findings of carditis as a major diagnostic criteria all chil-
dren with suspected ARF or PSRA should undergo an
echocardiogram as part their work-up.
Antibiotic prophylaxis in PSRA
In ARF long-term secondary antibiotic prophylaxis is
recommended. Thus, the question of secondary prophy-
laxis arises in PSRA patients. The 2009, American Heart
Association (AHA) Scientific Statement recommends
that patients with PSRA should be observed carefully for
several months for clinical evidence of carditis [7]. They
suggest that secondary prophylaxis be given for up to
one year after the onset of symptoms and discontinued
if there is no evidence of carditis. If valvular disease is
detected, the patient should be classified as having had
ARF and should continue to receive secondary
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prophylaxis. However, the effectiveness of this strategy is
not well established. The level of evidence (LOE) for this
recommendation is C - “only consensus opinion of
experts, case studies, or standard of care”, and IIb -use-
fulness/efficacy- less well established by evidence/
opinion.
Back to the cases
Case 1
The boy presents with additive arthritis with clinical and
serological evidence of a prior streptococcal infection,
but does not fulfill the Jones criteria. The probable diag-
nosis is PSRA. In line with the AHA recommendations,
the boy should be evaluated for signs of carditis clini-
cally and by echocardiogram, and treated with prophy-
lactic antibiotic for a year. After a year of treatment the
boy should be evaluated again for signs of carditis. If
carditis is not observed antibiotic prophylaxis should be
discontinued.
Case 2
In this case, the girl, at first, represents with fever and
monoarthritis. The most important entity to rule out is
septic arthritis, and a synovial fluid aspiration must be
done, and antibiotic treatment started. Later her arthritis
became migratory. Thus she fulfilled the Jones criteria
for the diagnosis of ARF with one major (migratory
arthritis) and two minor (fever and elevated ESR) cri-
teria. In line with the AHA recommendations, the girl
should start long-term secondary antibiotic prophylaxis.
Case 3
In this case, the girl presents with reactive arthritis,
with no clear evidence of streptococcal infection. The
girl did not have clinical tonsillitis, and basing the
diagnosis of PSRA on a single ASLO value is proble-
matic. She should be evaluated for clinical and echo-
cardiographic signs of carditis, and ASLO
measurement should be repeated in 2-4 weeks. If
ASLO titers demonstrate an increase she should be
treated as in case 1. If ASLO titers do not increase she
likely does not have PSRA and we believe that antibio-
tic prophylaxis is not justified.
Conclusions
Current knowledge supports the concept that PSRA is a
distinct entity from ARF based on clinical findings,
response to therapy and lack of cardiac involvement in
almost all cases (Table 3). It is not yet established
whether carditis is a late sequela of PSRA and if antibio-
tic prophylaxis should be given to PSRA patients. With
the current low level of evidence supporting prophylaxis
in PSRA, further studies in the form of a randomized
placebo controlled trial, are required.
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Table 3 Comparison of post-streptococcal reactive arthritis (PSRA) and acute rheumatic fever (ARF)
PSRA ARF
Age Bimodal: 8-14 years and 21-37 years 5-15 years with peak incidence around
12 years
Disease onset post streptococcal infection 7-10 days 10-28 days
Joint involvment Additive and persistent; large, small and axial joints Migratory, transient; mainly large joints
Acute phase reactants Moderatly elevated Markedly elevated
Response of arthritis to acetylsalicylic acid or
NSAID treatment
Poor to moderate Dramatic
Genetic markers Increased frequency of HLA DRB1*01 Increased frequency of the HLA
DRB1*16 allele
Carditis Conflicting reports, but uncommon Major diagnostic criteria, between 60-
70%




NSAID: Non-steroidal antiinflammatory drugs
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